Background {#Sec1}
==========

Alzheimer's disease (AD) is a complex illness \[[@CR1], [@CR2]\], influenced by both environmental and genetic risk factors \[[@CR3], [@CR4]\]. Amyloid (Aβ) burden increases with normal aging \[[@CR5]\], but extensive Aβ plaque depositions are a hallmark of AD, which may trigger a pathological cascade resulting in neuronal injury and cognitive impairment (i.e., Aβ hypothesis) \[[@CR6], [@CR7]\]. Under physiologic conditions, neuronally derived Aβ~42~ is balanced between production and clearance \[[@CR8]\], as soluble Aβ~42~ in the extracellular space is cleared by proteolysis, paravascular pathways, and blood-brain barrier transporters \[[@CR9]--[@CR11]\]. In AD, reduced clearance from the brain may result in a \~30% reduction of Aβ~42~ detected in the CSF of subjects with late-onset AD compared with healthy subjects \[[@CR8]\].

Inflammation (e.g., activated microglia, reactive astrocytes, pro-inflammatory cytokines) is also commonly found in AD brains \[[@CR12], [@CR13]\] and attributed to a potential immunogenicity of misfolded amyloid Aβ. This inflammatory response to pathological Aβ accumulation likely occurs decades prior to AD-associated cognitive decline \[[@CR14]\], but whether this response contributes to or is associated with amyloid accumulation is unknown. We recently showed that CD45^+^ leukocytes and pro-inflammatory cytokines in the cerebrospinal fluid (CSF) of subjects with amnestic mild cognitive impairment (aMCI), at a high risk for developing AD \[[@CR15], [@CR16]\], are present at levels equivalent to patients at the earliest stage of multiple sclerosis (MS), a central nervous system (CNS) autoimmune disease, confirming the presence of CNS inflammation \[[@CR17]\]. These data suggest that aMCI patients display features of CNS inflammation, although the impact this may have on brain amyloid deposition is unknown.

The purpose of this study was to investigate a potential relationship between adaptive immune cell populations and brain amyloid deposition. We assessed the profile of adaptive immune cells in the CSF, which is in close proximity to the brain, in contrast to previous studies that focused on the peripheral blood \[[@CR18]--[@CR22]\]. Thus, we quantified CSF- and blood-derived immune profiles by flow cytometry and ELISA, brain amyloid (Aβ) deposition by ^18^F-florbetapir positron emission tomography (PET) \[[@CR23]\], and soluble Aβ~42~ in the CSF by standard ELISA. We found that the extent of Aβ deposition correlated with a shift towards reduced frequencies of T cells and increased frequencies of memory B cells in the CSF. Additionally, CSF levels of the cytokine IL-6 correlated inversely with Aβ deposition. These data suggest that it is critical to identify novel risk factors that presage maladaptive immune mechanisms during AD \[[@CR17]\], as they hold the potential to become important immunotherapeutic targets for early intervention \[[@CR24]\]. These findings should be confirmed in a larger cohort collected at multiple centers.

Methods {#Sec2}
=======

All subjects signed written informed consent approved by the Institutional Review Boards of the UT Southwestern (UTSW) Medical Center and Texas Health Presbyterian Hospital of Dallas, Texas. The subjects (65.7 ± 6.0 years) were enrolled in a larger exercise study but gave consent for lumbar puncture, blood draw, and/or PET imaging at baseline prior to randomization in the exercise study. A 1:1 male-to-female ratio (12 males and 12 females) was maintained to reduce the confounder of sex bias. Six subjects did not have banked cells for apolipoprotein (APO)ε genotyping. All subjects underwent clinical interviews and a standard battery of neuropsychological tests to establish clinical diagnosis via multidisciplinary consensus using standard criteria by a licensed psychometrician at UT Southwestern. Detailed inclusion and exclusion criteria were published previously \[[@CR25]\]. Table [1](#Tab1){ref-type="table"} shows subject demographics, cognitive test results, sample collection, and APOε genotype for the 24 aMCI subjects. Of these, 17 had CSF, peripheral blood (PB), and PET imaging; 3 had CSF and PB but no PET imaging; 3 had PB and PET imaging but no CSF; 2 had PET imaging and CSF but no PB; and 1 had PB but no CSF or PET (subject 702).Table 1Subject demographicsSample collectionSubject numberAge/sexCDRMMSEImmediate recallDelayed recallCSFPBPET (mean SUVR)Genotype (ε3 or ε4)10559 M0.529119YYNANA70270 F0.52988NAYNANA71571 F0.52976YYNA3--471670 M0.530119YYNA3--371865 F0.5281413YNA1.253--472175 M0.5301610NAY1.202--372766 F0.528109YY1.18NA73258 F0.5301210YY1.263--473359 M0.5301311NAY1.213--373476 F0.5291310YY1.223--473574 F0.53077NAY1.163--373965 M0.5301311YY1.243--374573 M0.529127YNA1.553--475166 M0.52999YY1.203--375762 F0.5291414YY1.223--376758 F0.5301110YY1.163--376860 F0.53099YY1.09NA77170 M0.5301111YY1.093--378255 F0.528119YY1.083--378762 M0.5301211YY1.113--479461 M0.5301010YY1.21NA79570 M0.5291111YY1.273--382968 M0.53097YY1.20NA83164 F0.52988YY1.193--4Age is at time of sample collection*CDR* Clinical Dementia Rating, *MMSE* Mini-Mental State Exam, *CSF* cerebrospinal fluid, *PB* peripheral blood, *PET* positron emission tomography, *SUVR* standardized uptake value ratio, genotype shown for APOε status: *Y* yes, *NA* not available

CSF/peripheral blood lymphocytes collection and analysis {#Sec3}
--------------------------------------------------------

Sample collections occurred at the UT Southwestern Alzheimer's Disease Center, consistent with the NIA Biospecimen Best Practices Guidelines, using established protocols \[[@CR17]\]. Most sample collection was performed in the morning and initiation of sample processing occurred within 60 min of sample collection. Peripheral blood mononuclear cells (PBMC) were obtained via centrifugal Ficoll-based separation. CSF cells were obtained by centrifuging the CSF for 10-min at 394×*g* (4 °C) to collect the cell pellet at the bottom of the tube. The first 1 mL of CSF obtained during the lumbar puncture was discarded to minimize red blood cell contamination in the sample. CSF samples tinged red were not used. PBMCs and CSF cells were immediately stained with the fluorescent markers in parallel, and the resulting flow cytometry data was also acquired in parallel. The remaining PBMCs not used in the flow cytometry experiment were cryopreserved in media containing 50% human serum on the day of collection. This remaining PBMC sample was used for the APOε3/ε4 genotyping. CSF supernatant, blood plasma, and serum were aliquoted and stored at −80 °C for enzyme-linked immunosorbent assay (ELISA).

Flow cytometry {#Sec4}
--------------

CSF cells and PBMCs were resuspended with ice-cold FACS buffer (1× PBS, 4% BSA), and the cells were counted by a hemocytometer and verified by two team members, then stained with a multiplex panel consisting of CD45, CD4, CD8, CD19, CD27, and CD138 (BD Biosciences, San Jose, CA, USA) in parallel. CD3 was added to the flow panel after study of the first three aMCI subjects. No stains were used for live/dead cell exclusion since the cells were processed within an hour of collection. Gating strategies are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and are based on PBMC events. Cells were incubated on ice in the dark, washed once, resuspended in 1 mL FACS buffer, preserved (4% paraformaldehyde), and obtained within 3 days on a FACS Aria (BD Biosciences). Flow cytometry data were analyzed with Flowjo (Tree Star). All immune cell subtype frequencies were normalized to the CD45^+^ leukocyte gate to allow for comparison of the immune profile across samples. The innate cell population is defined as CD45^+^CD3^−^CD19^−^ \[[@CR17]\]. Data was acquired from all CSF cells obtained in the collection, and no minimum number of CSF cells was required to perform the flow cytometry experiments.

ELISA {#Sec5}
-----

Quantitation of antibody isotypes (IgG and IgM) and cytokines (VEGF, IL17, BDNF, IL-10, Il-6, and IFNγ) by ELISA was performed as previously published \[[@CR17]\]. Only IgG and IL-6 values are utilized in this study as the others did not display correlations with other parameters collected. For quantification of Aβ~42~, Innotest β-amyloid (1--42) ELISAs were performed as per manufacturer's instructions (Fujirebio, Malvern, PA, USA).

APOε genotyping {#Sec6}
---------------

For genotype analysis, one million PBMCs were thawed and DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen) as per the manufacturer's instructions. APOε genotype was performed using TaqMan SNP genotyping assays C904973_10 (rs7412) and C_3084793_20 (rs429358; Life Technologies). The genotype was performed by the DNA Genotyping Core at UT Southwestern Medical Center using an ABI 7900HT PCR instrument according to the manufacturer's instructions with modifications. Briefly, 10--20 ng/μL (3 μL) of DNA was added to each 96-well reaction plate containing 2.5 μL of reaction mix (2.5 μL TaqMan Master Mix, 0.225 μL ABI Probe (20×)). Allelic discriminations were performed using the thermal protocol of 50 °C for 2 min, 39 cycles of 95 °C for 15 s and 60 °C for 90 s, followed by a hold at 27 °C for 5 min. Genotype calls were determined using ABI Software SDS2.4.

PET imaging {#Sec7}
-----------

Participants were injected with a bolus of 10-mCi ^18^F-florbetapir 30 min prior to positioning in a Siemens ECAT HR PET scanner for a 10-min emission and 10-min transmission scan. A 2-min scout was acquired to ensure field of view without rotation in either the transverse or sagittal plane. At 50-min post-injection, two frames of 5-min PET emission scan and a 7-min transmission scan were acquired in a 3D mode using the following parameters: matrix size = 128 × 128, resolution at the image center = 5 × 5 mm, slice thickness = 2.42 mm, and field of view = 58.3 cm. Emission images were processed by iterative reconstruction, 4 iterations and 16 subsets with a 3-mm full width at half maximum (FWHM) ramp filter. The transmission image was reconstructed using back projection and a 6-mm FWHM Gaussian filter. Each PET image was spatially normalized to florbetapir uptake template (2 × 2 × 2 mm^3^ voxels) using SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK) and in-house MATLAB (Mathworks Inc., Natick, MA) scripts and visually inspected for registration quality. Standardized uptake value ratio (SUVR) was computed using mean cerebellar uptake as reference. Three regions-of-interest (ROI) relevant to AD pathology were selected a priori: posterior cingulate (PCC), precuneus, and mean cortex. The mean cortical SUVR was calculated by taking an average of posterior and anterior cingulate, precuneus, temporal, dorsolateral prefrontal, orbital frontal, parietal, and occipital SUVRs \[[@CR25]\].

Statistical analysis {#Sec8}
--------------------

All data are reported as mean ± standard deviation, with statistical significance set a priori at *p* \< 0.05 for all tests. A non-parametric Mann-Whitney test was used to compare immune cell population frequencies between APOε3 and APOε4 carriers. Spearman rank order correlations were performed to assess simple linear correlation for parameters including PET imaging, immune cell populations, and ELISA data. Multiple comparison correction was not performed for this exploratory study. All statistical analyses were performed using SPSS 20 (SPSS Inc.; Chicago, IL) and GraphPad Prism (La Jolla, CA).

Results {#Sec9}
=======

Cortical Aβ deposition coincides with decreased soluble Aβ~42~ in the CSF {#Sec10}
-------------------------------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} depicts representative PET imaging of cortical Aβ deposition in two aMCI subjects, including values for PCC and precuneous cortex, as early regions for amyloid deposition in AD \[[@CR26], [@CR27]\]. Mean SUVR amyloid burden for the entire brain (represented as "PET SUVR mean") of each subject is listed in Table [1](#Tab1){ref-type="table"}. All Spearman's rho values and *p* values for correlations are shown in Table [2](#Tab2){ref-type="table"}, and larger group PET data previously published \[[@CR25]\].Fig. 1PET reflects dysregulation of Aβ clearance. **a**, **b** Representative PET images and values corresponding to the standardized uptake value ratio (SUVR), with image of the posterior cingulate cortex (PCC). **c** Increases in PCC SUVR predict total amyloid burden (mean cortex). **d** PCC SUVR increase corresponds to a decrease in soluble CSF Aβ~42~. **e**, **f** Increases in precuneous cortex SUVR also predict total amyloid burden, but without the significant decrease in soluble CSF Aβ~42~. Linear regression (*solid lines*) and 95% confidence interval (*dotted lines*) shown. \**p* \< 0.05, \*\*\**p* \< 0.001 Table 2Spearman rank order correlations for PET amyloid deposition and immune profile in aMCI subjectsCerebrospinal fluid (CSF)Peripheral blood (PB)AgePET-PCCPET-precuneousPET-meanAβ~42~IL6IgGCD4 T cell\
%B cell\
%Memory B cell%Plasmab\
%T cell \#CD4 T cell \#CD4:CD8CD4 T cell%B cell\
%CD4:CD8Age*0.66*\*\**0.54*\*0.20−0.20−*0.63*\*−0.22**−** *0.49*\*0.290.39*0.60*\*\*−0.28−0.30−0.390.10−0.320.07PET-PCC*(0.002)0.49*\**0.49*\**−0.51*\*−*0.66*\*0.20−0.350.250.160.28−*0.57*\***−** *0.54*\*−0.200.16−0.280.12PET-precuneous*(0.013)(0.029)0.73*\*\*−0.36−0.450.002−0.390.100.380.39−0.12−0.21−0.22−0.34*0.58*\*\*−0.32PET-mean(0.39)*(0.027)(\<0.0001)*−0.52\*−0.060.04−0.310.09*0.56*\*0.18−0.13−0.22−0.05−0.33−0.43−0.35CSF \| Aβ~42~(0.38)*(0.030)*(0.14)*(0.029)*0.04−*0.45*\*0.17−0.17−0.40−0.230.350.390.360.170.230.25CSF \| IL6*(0.027)(0.038)*(0.19)(0.88)(0.90)0.170.68−0.02−0.51−0.520.160.130.340.010.570.14CSF \| IgG(0.33)(0.44)(0.99)(0.88)*(0.04)*(0.62)−0.10−0.19−0.39−0.16−0.35−0.25−0.010.29−0.060.22CSF \| CD4 T cell (%)*(0.047)*(0.22)(0.17)(0.28)(0.52)(0.86)(0.70)−0.46−0.05−0.210.47*0.59*\**0.67*\*\*−0.090.28−0.08CSF \| B cell (%)(0.21)(0.34)(0.69)(0.72)(0.46)(0.95)(0.44)(0.06)−0.020.17−0.47*−0.56\**−0.180.09−0.16−0.01CSF \| memory B (%)(0.09)(0.54)(0.13)*(0.02)*(0.08)(0.11)(0.10)(0.85)(0.93)0.370.080.01−0.32−*0.54*\*−0.34**−** *0.63*\*\*CSF \| plasmablasts (%)*(0.005)*(0.28)(0.12)(0.49)(0.33)(0.10)(0.50)(0.42)(0.47)(0.11)−0.04−0.08*−0.49*\*0.09−0.43−0.08CSF \| T cell (\#)(0.27)*(0.034)*(0.68)(0.65)(0.17)(0.68)(0.17)(0.06)(0.06)(0.76)(0.87)*0.95\*\**0.37−0.210.30−0.08CSF \| CD4 T cell (\#)(0.25)*(0.046)*(0.47)(0.44)(0.12)(0.74)(0.34)*(0.01)(0.019)*(0.99)(0.75)*(\<0.0001)0.50\**−0.140.09−0.03CSF \| CD4:CD8(0.13)(0.49)(0.45)(0.86)(0.15)(0.37)(0.97)*(0.003)*(0.49)(0.20)(0.05)(0.14)*(0.04)*0.130.170.19PB \| CD4T (%)(0.68)(0.56)(0.20)(0.22)(0.48)(0.97)(0.22)(0.73)(0.72)*(0.026)*(0.74)(0.41)(0.60)(0.63)0.20*0.94\*\**PB \| B cell (%)(0.13)(0.23)*(0.007)*(0.06)(0.30)(0.05)(0.79)(0.28)(0.49)(0.14)(0.06)(0.24)(0.72)(0.51)(0.40)0.18PB \| CD4:CD8(0.76)(0.65)(0.22)(0.19)(0.31)(0.70)(0.37)(0.75)(0.99)*(0.007)*(0.77)(0.76)(0.91)(0.45)*(\<0.0001)*0.18In the rho-value section of the table, rho-values that are significant are in italics and \* = \<0.05 and \*\* = \<0.01. Specific p-values are in parenthesis with significant values in italics

Amyloid deposition in the PCC and precuneous cortex occur early in AD patients \[[@CR4], [@CR6]\] and can predict conversion of aMCI to AD \[[@CR28]\]. In the aMCI cohort presented here, total cortical Aβ burden as measured by PET correlated with PCC SUVR (*r* = 0.49; *p* \< 0.05; Fig. [1c](#Fig1){ref-type="fig"}). However, total cortical Aβ burden as measured by PET correlated even more strongly with precuneous SUVR (*r* = 0.73; *p* \< 0.001, Fig. [1e](#Fig1){ref-type="fig"}). CSF Aβ~42~ levels were associated inversely with PCC Aβ burden (*r* = −0.51, *p* \< 0.05; Fig. [1d](#Fig1){ref-type="fig"}), but an inverted correlation of CSF Aβ~42~ levels with precuneous SUVR did not reach significance (*r* = −0.36, *p* \> 0.05). These data confirm that even in aMCI patients, Aβ deposition in the PCC (but not in the precuneous region) associates with loss of soluble Aβ~42~ in the CSF.

Reductions in CD4 T cells in the CSF positively associated with Aβ deposition in the PCC {#Sec11}
----------------------------------------------------------------------------------------

Others have reported that T cells are one critical component of Aβ~42~ clearance \[[@CR29]\]. Therefore, we examined the relationship between T cell frequency and Aβ deposition. We found that total T cells, and specifically the CD4 T cell subtype, were inversely associated with increased PCC Aβ burden (T cells: *r* = −0.57, *p* \< 0.05; CD4+ T cells: *r* = −0.54, *p* \< 0.05; Fig. [2a, b](#Fig2){ref-type="fig"}). There was no similar correlation within the CD8 T cell populations in either the CSF or periphery, or for the CD4:CD8 T cell ratio (Table [2](#Tab2){ref-type="table"}). Innate cell populations also did not correlate to age or Aβ burden in either the CSF or peripheral blood compartments (data not presented, but found in Additional file [2](#MOESM2){ref-type="media"}). As exacerbated disruption of Aβ~42~ clearance mechanisms have been observed in APOε4 carriers \[[@CR8]\] who are also at a greater risk for AD \[[@CR30]--[@CR32]\], we also examined T cell frequencies and Aβ deposition in APOε4 carriers and non-carriers (APOε3+). When considering genotype, we did not observe a generalized effect of APOε status on T cell populations in the CSF (Fig. [2c, d](#Fig2){ref-type="fig"}) or peripheral blood. Taken together, these data suggest a reduction in circulating CD4 T cells within the CSF is coincident with an accumulation of PCC Aβ independent of ApoE genotype.Fig. 2T cell numbers in the CSF decrease with increased amyloid burden. Both the **a** total number of T cells in the cerebrospinal fluid (CSF) and **b** the number of CD4+ T cells in the CSF decreases as amyloid burden identified by PET standardized uptake value ratio (SUVR) in the posterior cingulate cortex (PCC) increases. **c**, **d** APOε status does not affect T cell populations numbers or percent representation in the CSF. Linear regression (*solid lines*) and 95% confidence interval (*dotted lines*) shown. \**p* \< 0.05

B cells shift from the periphery to the CSF as Aβ burden increases {#Sec12}
------------------------------------------------------------------

As the other main effector cell of the adaptive immune system, we also investigated B cells subsets (i.e., naive, memory, and plasmablasts) in the CSF and peripheral blood, as well as immunoglobulin (Ig)G levels. Surprisingly, CSF levels of IgG (*r* = −0.45, *p* \< 0.05; Fig. [3a](#Fig3){ref-type="fig"}) were inversely associated with soluble Aβ~42~ in the CSF, suggesting that antibody accumulation in the CSF is coincident with the dysregulation of amyloid clearance. Within the CSF, the frequency of memory B cells positively associated with increased Aβ burden (*r* = 0.56; *p* \< 0.05; Fig. [3b](#Fig3){ref-type="fig"}). In contrast, peripheral blood B cells were inversely associated with precuneous Aβ burden (*r* = −0.58, *p* \< 0.01; Fig. [3c](#Fig3){ref-type="fig"}), though specific peripheral naïve and plasmablast B cell subsets remained unaffected by Aβ burden. Interestingly, the decline in peripheral memory B cells is associated with a decline in delayed recall (*r* = −0.46; *p* \< 0.05). Finally, CSF interleukin (IL)-6 was inversely associated with PCC Aβ burden (*r* = −0.66, *p* \< 0.05; Table [2](#Tab2){ref-type="table"}).Fig. 3B cells shift from the periphery to the CSF as amyloid burden increases. **a** Soluble IgG in the cerebrospinal fluid (CSF) declines with loss of soluble CSF Aβ~42~. **b** Increased mean standardized uptake value ratio (SUVR) for the total cortex correlates to an increase in memory B cell percent representation in the CSF, while **c** increased Aβ deposition in the precuneous cortex associates with a decline in B cell representation in the peripheral blood. **d** Soluble Aβ~42~ in the cerebrospinal fluid (CSF) is decreased in APOε4+ subjects. **e**, **f** Apoε4 carriers exhibit enhanced memory B cell percent representation in the CSF, but genotype did not affect overall B cell distribution

APOε4 may also affect B cell function, as B cells highly express the APOε receptors necessary for APOε clearance of Aβ \[[@CR33], [@CR34]\]. We found that APOε4 carriers had significantly lower CSF Aβ~42~ compared to APOε3 subjects (APOε3^+^: 1214 ± 227 pg/mL vs. APOε4^+^: 788 ± 430 pg/mL; *p* \< 0.05; Fig. [3d](#Fig3){ref-type="fig"}). We compared B cell subtype frequencies in APOε4 and APOε3 carriers and found no statistical difference between B cell numbers (Fig. [3e](#Fig3){ref-type="fig"}). However, APOε4 carriers exhibited a significantly lower frequency of naïve B cells, and a higher frequency of memory B cells, in the CSF (Fig. [3f](#Fig3){ref-type="fig"}). This effect of genotype was not observed in the peripheral B cell pools. Thus, the loss of B cells from the periphery, and the gain of memory B cells in the CSF, is highly suggestive of an adaptive humoral immune response concomitant with increased Aβ burden.

Discussion {#Sec13}
==========

While Aβ burden is a hallmark of AD, we are only beginning to understand the impact of neuroinflammation on AD pathology. To this end, we and others have investigated the immune profile of patients at high risk to develop AD and reported potential involvement of multiple inflammatory components in AD onset and progression \[[@CR17], [@CR29]\]. However, given that Aβ deposition is a common feature of AD, it stands to reason that there may be a relationship between Aβ deposition and the immune profile as part of an endogenous immune response associated with early AD pathology. Since the interplay of these two factors remains largely unknown, we investigated the relationship between PET Aβ imaging, CSF Aβ~42~ levels, and the immune profiles in the CSF and blood of a well-documented cohort of aMCI patients \[[@CR17], [@CR25]\] prodromal for AD. Dysregulation of Aβ~42~ clearance is thought to occur \~10 years preceding AD diagnosis \[[@CR8]\] and likely to be exacerbated in aMCI. Aβ~42~ production is also reported to be proportional to neuronal activity and highest in the PCC and precuneus cortex, which are components of the default-mode network (DMN) and affected in AD \[[@CR26], [@CR27], [@CR35], [@CR36]\]. In addition, higher Aβ burden in the precuneous cortex most accurately predicts conversion of aMCI to AD \[[@CR28]\]. Therefore, we focused on these regions for our analyses.

Within the T cell populations in the CSF of aMCI subjects, reduction in the CD4 T cell frequency is associated with increased Aβ burden (summarized in Fig. [4](#Fig4){ref-type="fig"}). This observation may reflect the loss of T cell activation and expansion and corroborates our previous findings in a smaller cohort of aMCI patients in which we observed a reduction of CD4+ T cells in the CSF in comparison to younger patients with a known CD4 T cell-mediated neurological disease of the CNS \[[@CR17]\]. Despite this correlation of reduced T cell frequency and increased Aβ burden, we did not find any significant relation between T cell frequency and global cognitive or memory function in our aMCI cohort as assessed by MMSE and immediate and delayed recall (Additional file [2](#MOESM2){ref-type="media"}). Others have also observed no correlation of activated CD4 T cells with a battery of cognitive domain tests in aMCI subjects (*n* = 19) \[[@CR29]\]. It is thought that T cells in the CSF would typically mediate an Aβ~42~-directed immune response to clear amyloid from the brain \[[@CR37]\], which should result in improved cognition and brain health. However, the aMCI cohorts in our study or the Lueg study do not support this concept. It is possible that such correlations cannot be observed except in more advanced disease, and indeed, in the Lueg study, activated CD8 T cells correlated with neurocognitive deficits in AD subjects. These results highlight the need for longitudinal multi-center investigations of the immune profiles of aMCI subjects in order to understand the potential roles of T cells in the advancement of this devastating disease.Fig. 4Summary of adaptive immune changes in the CSF with amyloid deposition. This figure highlights the findings that CSF lymphocyte populations shift from high CD4 T cells to high memory B cells with increased Aβ deposition in the brain. This also includes a reversal the IgG:soluble Aβ~42~ levels with increased amyloid burden

Increased cortical Aβ burden in our aMCI cohort correlated with decreased frequency of peripheral CD19+ B cells, similar to other results in AD \[[@CR22]\]. This finding suggests that egress of B cells from the peripheral compartment may be an early event associated with AD development and emphasizes an urgent need to identify critical factors that may mediate egress of B cells into the CNS. Even more importantly, cortical Aβ burden correlated with a shift from naïve to memory B cell subsets in the CSF, independent of age (summarized in Fig. [4](#Fig4){ref-type="fig"}). Naive B cells proliferate and differentiate into memory B cells upon initial exposure to their cognate antigen. These memory B cells circulate indefinitely until subsequent encounter with their cognate antigen elicits a rapid and enhanced adaptive immune response \[[@CR38]\]. Although the antigen(s) driving this shift to memory B cells in the CSF of aMCI patients remains unknown, it is possible that the memory B cell pool is enriched for Aβ~42~-reactive B cells that are long-lived and poised for rapid differentiation to antibody secreting plasmablasts and plasma cells.

Re-activation of memory B cells following antigen exposure induces conversion to plasmablasts and plasma cells that secrete antibody, which may be important for Aβ clearance \[[@CR39], [@CR40]\]. In fact, the intent of potential therapies of active Aβ immunization is to promote the production of anti-Aβ antibodies by resident plasmablasts and plasma cells \[[@CR41]--[@CR43]\]. The role of plasmablasts in Aβ clearance remains unclear, although we did observe a significant correlation between the frequency of plasmablasts in the CSF and amyloid depostion (Supplemental data). Interestingly, the plasmablast survival factor, IL-6 \[[@CR44]\], was also decreased in the CSF supernatants of our aMCI cohort and this decrease correlates with increased Aβ burden. This finding could indicate either impaired ability for various cell types of aMCI patients to produce IL-6, or that emerging plasmablasts are rapidly consuming available IL-6. Of note, memory B cells display an increased IL-6 output with advancing age \[[@CR44]\], but we could not verify this finding by others as the small sample size for our exploratory cohort precludes controlling our results by subject age. The consequences of IL-6 availability and impact of this antibody secreting B cell subtype in AD neuropathology or neuroprotection requires further investigation in a cohort of patients powered to control for possible age-related confounders.

It is well-established that the APOε4 genotype is associated with Aβ burden in AD \[[@CR45]\]. It has also been known since 1998 that B cells express the low-density lipoprotein (LDL) receptor (LDLR) \[[@CR34]\], the main receptor for cholesterol metabolism that binds APOε3 and APOε4 to modulate inflammation \[[@CR46]--[@CR48]\]. Peripheral B cells are capable of internalizing and degrading LDL, with an increased capacity for degradation upon immune activation \[[@CR34]\]. But while B cells express the APOε receptors necessary for APOε-mediated clearance of Aβ from the brain \[[@CR33], [@CR34]\], there are no studies investigating the effect of APOε genotype on endogenous B cell function. We found that the frequency of antigen-experienced memory B cells in the CSF was elevated in APOε4^+^ aMCI patients compared to APOε3^+^ aMCI patients. Yet APOε4^+^ aMCI patients also displayed decreased CSF Aβ~42~ in comparison to APOε3^+^ aMCI patients. These observations may indicate that the humoral immune response against Aβ~42~ is defective in the at-risk CNS or that the memory B cell pool is responding to other factors enriched in the at-risk CNS that would cause their expansion in a bystander-like fashion.

Finally, innate cells, operating as antigen-presenting cells (APC), are required to activate adaptive immune components, including T cells and B cells \[[@CR47], [@CR49]\]. This emphasizes the profound impact defective innate cells can have on adaptive immunity, including amyloid clearance \[[@CR50]\]. We found that CD45^+^ leukocytes and pro-inflammatory cytokines were present in the CSF of aMCI patients, at levels equivalent to or exceeding those found in early MS patients \[[@CR17]\], a prototypical inflammatory CNS disease \[[@CR51]\]. Innate cell population frequencies did not, however, correlate with amyloid deposition. Unfortunately, our flow cytometry panel precludes identification of specific innate cell subsets. Others have not found differences in monocytes, NK cells, and NK T cells in aMCI or AD patients compared to healthy controls \[[@CR29]\], but the specific relationship remains to be determined with regard to the AD pathology as revealed by PET amyloid imaging.

Conclusions {#Sec14}
===========

A recent AD review \[[@CR52]\] called for targeted investigation of potentially beneficial CNS-directed autoreactivity that may mediate protection from neurodegeneration. However, the role of amyloid deposition in the progression of AD, or in relation to neuroinflammation, remains in question, with arguments both supporting \[[@CR53]\] and rejecting \[[@CR54]\] a foundational role for Aβ~42~ deposition in the initiation and/or progression of AD. Despite the limitations of a small sample size and cross-sectional nature of the present study, our data reveal several potentially important relationships between the adaptive immune system and brain amyloid deposition in patients with aMCI. Future studies are warranted to reliably quantify changes in leukocyte populations with regard to both brain Aβ burden using PET amyloid imaging, as well as stratifications by APOε genotype. Mechanistic studies are also needed to determine whether dysregulation of the immune system contributes to the increase of amyloid burden in and/or Aβ~42~ clearance from the CNS.

Additional files
================

 {#Sec15}

Additional file 1: Figure S1.Gating strategy for lymphocyte analysis in the blood and CSF. Top row shows initial gating strategies to identify live cells from FACS, which are further subdivided as CD45+ leukocytes (row 2). CD45+ populations are parsed into CD3+ T cell populations (right side) and CD19+ B cell populations (left side), with individual lymphocyte subsets identified. (JPG 295 kb) Additional file 2:Complete table of all Spearman rank order correlations performed for the manuscript. (XLSX 88 kb)

AD

:   Alzheimer's disease

aMCI

:   Amnestic mild cognitive impairment

APOε

:   Apolipoprotein E

Aβ

:   Amyloid beta

CDR

:   Clinical Dementia Rating

CNS

:   Central nervous system

CSF

:   Cerebrospinal fluid

DMN

:   Default-mode network

ELISA

:   Enzyme-linked immunosorbent assay

IL

:   Interleukin

MMSE

:   Mini-Mental State Exam

MS

:   Multiple sclerosis

PB

:   Peripheral blood

PBMC

:   Peripheral blood mononuclear cells

PCC

:   Posterior cingulate

PET

:   Positron emission tomography

SUVR

:   Standardized uptake value ratio

UTSW

:   UT Southwestern
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